News

The approval was backed by the results of RAD001 In Advanced Neuroendocrine Tumors (RADIANT-3) Phase III trial which demonstrated that the treatment with Afinitor more than doubled the

Currently, the company is in quest of a partner who can fund further development and marketing of the product. Centre for Endocrinology and Diabetes Sciences clinical professor David

The Phase 2 trial – Allogeneic Mesenchymal precursor cell Infusion in myoCardial Infarction (AMICI) – is expected to initially enroll patients at multiple European sites, including in the

The new facility will allow voluntary testing and auditing program that helps dietary supplement manufacturers ensure and attest to the production of quality products for consumers. USP’s new

Switzerland-based Acino is a developer and manufacturer of generic and pharmaceuticals using advanced drug delivery technologies, for which it also holds patents. Berlin Pharma CEO Amal Naj said

The agreement enables Zetes to sell, install and support Systech’s serialization solution throughout Europe. Systech Europe general manager Frederic Menardo said Zetes has experience in the pharmaceutical and

The company’s decision is supported by the US Food and Drug Administration (FDA). Before coming to this decision, the company has evaluated and reported two serious adverse events

Addex entered an exclusive collaboration and license agreement with Merck, through its affiliate Merck Sharp & Dohme Research, in late 2007, to develop a new class of orally

IMCD is a provider of sales, marketing and distribution of specialty chemicals and food ingredients. CPME makes a clear separation of water phase and organic phase, which means